Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma

Bookmark and Share
Published: 12 Dec 2017
Views: 1999
Rating:
Save
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

Prof Dimopoulos speaks with ecancer at the 2017 ASH annual meeting about the phase 3 ALCYONE study, looking at daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma patients ineligible for transplant. 

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.